SAMS Statement on Passage of The Consolidated Appropriations Act of 2023
WASHINGTON, D.C., December 23, 2022 – The Securing America’s Medicines and Supply (SAMS) Coalition today congratulated the Administration and Congress for meeting the needs of the American people and including critical public health provisions in the end of year appropriations package.
Specifically, SAMS highlighted increases to the federal funding levels for key agencies like the Biomedical Research and Development Agency (BARDA) and the Strategic National Stockpile (SNS), as well as standing programs like Project BioShield.
The Coalition also expressed support for the inclusion of provisions from the PREVENT Pandemics Act. Specifically, investments in forward-thinking SNS arrangements and the stockpiling of medical countermeasures and essential medicines like antibiotics comes at a critical juncture in our public health.
“The public health provisions included in the FY23 omnibus appropriations package represents a serious investment in our Nation’s preparedness capabilities,” said David Sanders, Executive Director of SAMS and Vice President of Government Affairs and Policy at Coherus BioSciences. “We thank the Biden-Harris Administration and Congressional leadership for their bipartisanship and commitment to securing our country’s medicine cabinet.
The Coalition looks forward to advocating for additional preparedness measures in the 118th Congress.
About Securing America’s Medicines and Supply
Securing America’s Medicines and Supply (SAMS) is a multi-industry coalition of companies with the mission to strengthen the security of the medical supply chain in the United States. SAMS seeks to drive the implementation of legislation and regulation to reward and foster U.S.-made manufacturing of important pharmaceutical products, devices, and supplies. SAMS supports U.S. patients, domestic healthcare security, and U.S. jobs.
Read SAMS’ summary of the omnibus appropriations bill here: